Graft Rejection

Graft Rejection is a complex immunological response in which the recipient's immune system recognizes and attacks a transplanted organ or tissue as foreign. The immune response involves both cellular and humoral components, aiming to eliminate the perceived threat posed by the graft. T cells play a central role in cell-mediated rejection, recognizing foreign antigens on the graft and initiating an immune response. Additionally, antibodies produced by B cells contribute to humoral rejection by targeting specific antigens on the graft's cells. The major histocompatibility complex (MHC) plays a crucial role in graft rejection, as disparities between donor and recipient MHC molecules can trigger immune responses. Acute rejection occurs within days to weeks after transplantation, while chronic rejection develops over a more extended period, often leading to graft failure. Immunosuppressive drugs, such as corticosteroids and calcineurin inhibitors, are commonly used to dampen the immune response and prevent rejection. Despite advances in immunosuppression, graft rejection remains a significant challenge in transplantation medicine. Research aims to develop novel strategies to induce immune tolerance and minimize the risks associated with graft rejection, ultimately improving the long-term success of organ and tissue transplantation. Understanding the immunological mechanisms involved in graft rejection is crucial for refining therapeutic approaches and enhancing the outcomes of transplantation procedures.